Lipomatous Tumors Panel

Test Information

This is a comprehensive panel testing for gains, losses and LOH in the liposarcoma specimens along with TP53 targeted mutation analyses. The test is performed in somatic tissue testing via the OncoScan assay; it can identify chromothripsis (genomic instability in the tumor specimens) and copy number gains, losses and LOH of the ALT tumor associated markers along with TP53 hotspot mutation testing analyses. Data analysis, interpretation and reporting are performed adhering to the ACMG clinical laboratory standards for microarray analysis for neoplastic specimens and next-generation sequencing (Genetics in Medicine (2013) 15(9): 733-747).

Turnaround Time

10 days

CPT Code(s)




Clinical Information

Liposarcomas are among the most common soft tissue sarcomas with an incidence rate of 0.4-1.1 per 100,000 people depending on gender and race. This heterogeneous group of neoplasms is classified into various categories depending on histology, molecular signature, and behavior. Liposarcomas can be: 1) well-differentiated/atypical lipomatous tumors 2) dedifferentiated 3) myxoid (round cell) or 4) pleomorphic. Since the first consistent chromosomal aberration was reported in 1986, cyto- and molecular genetic techniques have been integral in characterizing these tumors.


Gene sequencing and targeted mutation testing and copy number analysis can serve as a useful diagnostic and potentially prognostic tool for the analysis of affected tissues or tumors. The detection of copy number variants or specific gene mutations may enhance treatment decisions.

Specimen Requirements

Analysis can be performed on fresh or frozen tissue samples as well as formalin-fixed, paraffin-embedded tissue samples.

Transport Instructions

The specimen should be kept at the appropriate temperature and delivered via overnight shipping.

Have Questions Need Support?

Call our laboratory at 1-800-473-9411 or contact one of our Laboratory Genetic Counselors for assistance.
Robin Fletcher, MS, CGC
Kellie Walden, MS, CGC

Oncology Testing, Panel
Meet Reggie Roper

Meet Reggie Roper

Reggie has been part of the GGC family for over 18 years. He has short stature, webbing of his hands, pulmonary stenosis, seizures and hydrocephalus along with developmental delay. He carried an initial diagnosis of cardiofaciocutaneous (CFC) syndrome; however, as genetic testing advanced, GGC made the diagnosis of Noonan-like syndrome with loose anagen hair by identifying a mutation in the SHOC2 gene. He is also an active participant in the Greenwood Community Theatre's Penguin Project. "GGC is...

In The News